ZAI LAB LIMITED Defined Contribution Plan, Cost
ZAI LAB LIMITED (ZLAB) reported Defined Contribution Plan, Cost of $17.61 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2022-03-01
- ZAI LAB LIMITED defined contribution plan, cost for fiscal 2021 was $17.61M, a 302.61% increase from fiscal 2020.
- ZAI LAB LIMITED defined contribution plan, cost for fiscal 2020 was $4.37M, a 19.11% decline from fiscal 2019.
- ZAI LAB LIMITED defined contribution plan, cost for fiscal 2019 was $5.41M, a 279.37% increase from fiscal 2018.
- ZAI LAB LIMITED defined contribution plan, cost for fiscal 2018 was $1.43M.
| Period end | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|---|
| 2021-12-31 | $17.61M 10-K · filed 2022-03-01 | ||
| 2020-12-31 | $4.37M 10-K · filed 2022-03-01 | ||
| 2020-06-30 | $2.42M 6-K · filed 2020-09-11 | ||
| 2019-12-31 | $5.41M 10-K · filed 2022-03-01 | ||
| 2019-06-30 | $2.30M 6-K · filed 2020-09-11 | ||
| 2018-12-31 | $1.43M 10-K · filed 2021-03-01 | $1.42M 20-F · filed 2019-03-29 | |
| 2017-12-31 | $579.00K 20-F · filed 2020-04-29 | $579.09K 20-F · filed 2018-04-30 | |
| 2016-12-31 | $288.67K 20-F · filed 2019-03-29 | ||
| 2015-12-31 | $79.88K 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |